-
Mashup Score: 3Immune Monitoring and Discovery Platform | OSUCCC – James - 8 day(s) ago
Discover the resources available to OSUCCC – James cancer researchers through the Immune Monitoring and Discovery Platform Shared Resource.
Source: cancer.osu.eduCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Biomarker testing in NSCLC: patient and caregiver awareness and understanding | COR2ED - 11 day(s) ago
We are pleased to share findings from a PRECISION ONCOLOGY CONNECT survey that were presented as a poster at ESMO 2024. A group of international
Source: cor2ed.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 11
Research seeking to solve the mystery of the legendary explorer’s birthplace will feature in a documentary.
Source: www.bbc.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5OSUCCC – James 25th Annual Scientific Meeting 10/10/2024 - 29 day(s) ago
Register now for the Annual Scientific Meeting (ASM) – a meeting that reflects the breadth of our cancer program and offers the opportunity to feature important work by our scientists, foster new research collaborations, provide an avenue for feedback and further our work toward creating a cancer-free world. 10/10/2024
Source: cancer.osu.eduCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 31Early detection of ovarian cancer using cell-free DNA fragmentomes and protein biomarkers - 1 month(s) ago
Abstract. Ovarian cancer is a leading cause of death for women worldwide in part due to ineffective screening methods. In this study, we used whole-genome cell-free DNA (cfDNA) fragmentome and protein biomarker (CA-125 and HE4) analyses to evaluate 591 women with ovarian cancer, benign adnexal masses, or without ovarian lesions. Using a machine learning model with the combined features, we detected ovarian cancer with specificity >99% and sensitivity of 72%, 69%, 87%, and 100% for stages I–IV, respectively. At the same specificity, CA-125 alone detected 34%, 62%, 63%, and 100% of ovarian cancers for stages I–IV. Our approach differentiated benign masses from ovarian cancers with high accuracy (AUC=0.88, 95% CI=0.83-0.92). These results were validated in an independent population. These findings show that integrated cfDNA fragmentome and protein analyses detect ovarian cancers with high performance, enabling a new accessible approach for noninvasive ovarian cancer screening and diagnost
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 19New diagnostic and nonsurgical local treatment modalities for early stage lung cancer - 2 month(s) ago
Exciting advancements have emerged in the field of early-stage lung cancer diagnosis and treatment, leading to the development of new diagnostic and nonsurgical local treatment modalities. These innovative approaches aim to provide accurate and less invasive options for patients.
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 27Sarcopenia as a Predictive Factor for Carboplatin Toxicity in Patients with Advanced Non-Small Cell Lung Cancer - PubMed - 3 month(s) ago
Sarcopenia in cancer patients often negatively impacts various outcomes. Carboplatin, a first-line chemotherapy for non-small cell lung cancer (NSCLC), is dosed based on body weight, which doesn’t account for sarcopenia. This study evaluated the association between sarcopenia and carboplatin-related …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 44FDA Grants Accelerated Approval to Repotrectinib for NTRK Fusion–Positive Solid Tumors - 5 month(s) ago
Today, the FDA granted accelerated approval to repotrectinib (Augtyro) for adult and pediatric patients aged 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTR…
Source: ascopost.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 44FDA Grants Accelerated Approval to Repotrectinib for NTRK Fusion–Positive Solid Tumors - 5 month(s) ago
Today, the FDA granted accelerated approval to repotrectinib (Augtyro) for adult and pediatric patients aged 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTR…
Source: ascopost.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 17Multi-cancer early detection (MCED) tests: prioritizing equity from bench to bedside - 5 month(s) ago
Multi-cancer early detection (MCED) tests are blood-based tests designed to screen for signals of multiple cancers. There is growing interest and investment in examining the potential benefits and applications of MCED tests. If MCED tests are shown to …
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
RT @OhioStatePIIO: 🚨JOB ALERT🚨 #PIIO #ImmuneMonitoring & Discovery Platform (https://t.co/OuGHnXMT0M) seeks a Sr. Research Scientist w/ at…